Amyloid-Lowering Agents

Monoclonal Antibodies

BACE1 Inhibitors

Gamma-secretase Inhibitors

Immunotherapy

Aggregation Inhibitors

Aducanumab

Lecanemab

binds to aggregated AB

binds to amyloid fibrils
(prevents aggregation)

Active immunisation

Passive immunisation

vaccines

exogenous antibodies

Prevents cleaving of APP

prevent monomers from becoming oligomers

Limitations

Efficacy challenges
(especially in late-stage AD)

ARIA
(edema/hemorrhages in MRI)

intervention must be early

Expensive

References

Cummings 2023